Trial Profile
Phase 1/2 Study of REGN4336 (a PSMAxCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab or REGN5678 (a PSMAxCD28 Bispecific Antibody) in Patients With Metastatic Castration-Resistant Prostate Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary) ; REGN 4336 (Primary) ; REGN 4336 (Primary) ; Sarilumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 05 Feb 2024 18F-DCFPyL has been removed from the study Sarilumab and REGN5678 has been added to this study, hence number of treatment arms has been changed to 3,planned number of patients changed from 199 to 370.
- 05 Feb 2024 Planned End Date changed from 4 Aug 2026 to 14 Jan 2027.
- 05 Feb 2024 Planned primary completion date changed from 4 Aug 2026 to 14 Jan 2027.